game changer

Tech company uses machine learning to buy homes in Houston

This Houston company has the key to a more exact searching process when it comes to finding a new home to buy. Courtesy photo

For most consumers, the home buying process includes a very specific online search. People specify their neighborhood requirements, the number of bedrooms or bathrooms, backyard size, and more — yet still, the search results in a staggering amount of homes. It's way more than anyone can reasonably look at.

That's where Martin Kay and Entera Technology, the company he founded and is CEO of, come in. Kay, a 20-year veteran of the tech sector, who's bought multiple homes as rental properties, realized the way to solve the problem of that kind of search engine overload was through machine learning. He now works with some of the largest home-buying companies in the world, helping them find properties that match the specifications they have to attract the clients they want.

"All residential real estate is a consumer product," he says. "Ultimately, the people who are going to live in that home care most about, is it a nice home with a big backyard neat good schools, is it safe? The [home buying] companies are trying to figure out what do the end consumers really care about so we can give them exactly what they need?"

To do so, Entera collects data — lots and lots of it. Kay and his team have taught their software programs what a chef's kitchen is, for example. They did so by compiling tens of thousands of photos of kitchens and telling the software, "This is a kitchen." Then, they taught it to recognize what makes a chef's kitchen — a larger size, more than one sink, high-end appliances. They used the same techniques in identifying things like millennial-friendly neighborhoods or neighborhoods that were up-and-coming on the real estate scene. They draw from listings available with the Houston Association of Realtors and beyond, a vast array of tens of thousands of homes.

Officially launched in 2017, Entera blends its data collection and analysis with on-the-ground service. After Entera's proprietary software collects what it thinks home-buying companies want, members of Entera's service team go out to look at the homes.

"We're a little bit like Netflix," he says. "They go out and get content from everyone, and they begin to watch your behavior. So, Netflix has 2,000 profiles and you probably fit five or six of those. We have almost 100 profiles and what we do is say, we're going to understand what you want, watch your behavior and instead of giving you 40,000 properties on a big map, we actually match you based on your preferences, to the five or six houses that are best for you."

While Entera has been working with larger home-buying companies — like firms that buy tens of thousands of homes every year — Kay says they have begun working with smaller entities, and he figures within the next few years, Entera will be using the same data collection and machine learning to work with individual home buyers.

Based in Houston, Entera has operations in New York and San Francisco as well. The company has 17 full-time employees, along with approximately 100 contractors in its markets. And while Kay understand a human touch is needed in business, he loves that he can use a data model to present unbiased opinions to his clients.

"[Real estate] actually affects people's lives meaningfully," Kay says. "Real estate data — where you live, what your neighborhood is, how you make that choice — …this data matters to people in a way they can tangibly touch and understand and feel. We can help people make what are big, complex choices that are often highly ambiguous. I love it because it matters. You can measure how it matters immediately."

Data-driven tech

Courtesy of Entera

Entera focuses on collecting data and analysis and pairs it with on-the-ground service. After Entera's proprietary software collects what it thinks home-buying companies want, members of Entera's service team go out to look at the homes.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted